7 min learn
This story initially appeared on PennyStocks
Will These Biotech Penny Shares Pop Subsequent Month?
Biotech penny shares have turn out to be a few of the hottest shares to observe all through the Covid pandemic. And whereas the plain clarification for that is the connection between biotech and Covid, there are some much less apparent elements to think about.
For one, the pandemic has helped to emphasise a wide range of biotech corporations that aren’t engaged on a Covid therapy. It’s because buyers have continued to deal with corporations which have a big pipeline of promising belongings reasonably than ones solely engaged on a vaccine or therapy.
The subsequent factor to think about is that there are lots of biotech penny shares engaged on both therapies or vaccines for Covid-19. These corporations will be extra risky than others, however the potential can be fairly excessive.
4 Biotech Penny Shares to Watch Proper Now
Now, when in search of a biotech penny inventory to purchase, there are some things to think about. At the start is, what does its pipeline seem like? This contains understanding what number of medicine it has in growth, and the place these medicine are within the numerous levels of approval.
[Read More] 3 Penny Shares on Robinhood for Your April Watchlist
Subsequent, how is its monetary scenario? Has it engaged in any fundraising rounds or does it have a big stability of money available? This info may help to establish potential long-term enterprise alternatives and whether or not or not it could fund ongoing/future trials and analysis.
These are all equally essential points to think about for all potential biotech buyers. So with this in thoughts, are these the highest penny shares to purchase for Might 2021?
- Iterum Therapeutics Plc. (NASDAQ: ITRM)
- Onconova Therapeutics Inc. (NASDAQ: ONTX)
- Asensus Surgical Inc. (NYSE: ASXC)
- Zomedica Corp. (NYSE: ZOM)
1. Iterum Therapeutics Plc. (NASDAQ: ITRM)
Iterum is a clinical-stage pharmaceutical firm engaged on the manufacturing of anti-infectives. These compounds are used for quite a lot of drug-resistant pathogens world wide. Its flagship compound referred to as sulopenem is a novel anti-infective that’s presently in a Part 3 trial to see its efficacy in treating antibiotic-resistant anaerobic infections.
Iterum states that it has acquired QIPD or Certified Infectious Illness Product and Quick Observe Designations for each the oral and intravenous formulations of sulopenem in seven completely different indications. Final month, Iterum introduced its fourth quarter and full-year 2020 outcomes.
[Read More] High Penny Shares This Week? 3 To Watch Throughout Crypto Increase
Corey Fishman, CEO of the corporate said that “Iterum has made glorious progress in the previous couple of months and we stay up for persevering with that momentum all through 2021. Within the fourth quarter of 2020, we submitted a New Drug Utility (NDA) for oral sulopenem for the therapy of uncomplicated urinary tract infections in sufferers with a quinolone non-susceptible organism, which is presently underneath evaluate by the FDA with a July twenty fifth, 2021 Prescription Drug Person Price Act (PDUFA) objective date.”
Solely a month earlier than this, the corporate introduced the rise of its share providing to 40 million shares, bringing in mixture internet proceeds of round $42.1 million. This could assist to fund the remainder of the sulopenem trial in addition to the industrial launch of this compound. Contemplating its position within the biotech business, is ITRM inventory value watching?
2. Onconova Therapeutics Inc. (NASDAQ: ONTX)
Onconova is one other pure-play biotech penny inventory engaged on clinical-stage prescription drugs. Its focus is on therapies for most cancers, together with focused anti-cancer therapeutics that disrupt particular mobile pathways. This contains its proprietary multi-kinase inhibitor referred to as ON-123300. This compound is starting a dose-escalation and growth Part 1 trial within the U.S. The info from this examine must be coming within the second quarter of this yr.
Moreover, an analogous trial is presently ongoing in China. One other fascinating a part of its pipeline is the compound rigosertib. That is in preclinical trials proper now for its efficacy in treating Covid-19.
On April twenty second, the corporate introduced that its first affected person was dosed in an investigator-initiated Part 2 examine of rigosertib in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma (RDEB).
Steven Fruchtman, M.D., CEO of Onconova, said that “we’re happy with the development of our investigator-initiated packages with rigosertib, and to supply rigosertib in help of this essential Part 2 investigator-sponsored examine…We hope rigosertib can show helpful to this uncommon affected person inhabitants with an incredible unmet medical want.”
This comes only some weeks after the corporate introduced full enrollment within the second cohort of its China-based examine of ON-123300 with HanX Biopharmaceuticals. On this trial, the objective is to see ON-123300’s efficacy within the therapy of metastatic breast most cancers and different superior refractory cancers.
Contemplating its thrilling pipeline, it appears like Onconova may very well be an fascinating penny inventory to observe. Moreover, shares of ONTX inventory have jumped by round 47% YTD, together with a double-digit achieve on April twenty second. Whether or not this places it in your watchlist is as much as you.
3. Asensus Surgical Inc. (NYSE: ASXC)
Asensus Surgical is penny inventory that we’ve coated fairly a number of occasions previously few months. The reason is, its stable pipeline of doubtless helpful belongings. The corporate states that it’s creating “a brand new customary of surgical procedure for elevated management, much less variability and constantly superior outcomes.”
Its principal product goals to make use of AI to enhance the outcomes of each frequent and extra intensive surgical procedures. Nearly all of its market relies on offering the instruments to conduct elective surgical procedures extra safely and successfully.
When the pandemic first started, many people determined to forgo elective surgical procedures in the intervening time. Nonetheless, because the months handed and circumstances dropped, these surgical procedures started to happen at virtually pre-covid ranges.
[Read More] 4 Trending Penny Shares to Watch in April 2021
Due to this, some buyers consider that Asensus and its flagship Efficiency-Guided Surgical procedure merchandise might see a significant improve in demand within the coming months or years. This contains its Senhance Surgical System, which lately acquired an expanded 510(ok) clearance to be used usually surgical procedure purposes.
Moreover, its Clever Surgical Unit, or ISU, lately was awarded a CE Mark in Europe. Within the newest fourth-quarter end result, the CEO of the corporate gave a press release relating to the corporate’s present and future operations.
“We’re very happy with the momentum we generated throughout 2020 and significantly throughout the fourth quarter. This momentum continued into the early a part of 2021 the place we have now already completed quite a lot of important milestones, together with the bolstering of our stability sheet, the rebranding of the group, and the introduction of our imaginative and prescient for Efficiency-Guided Surgical procedure.”
CEO of Asensus Surgical Inc., Anthony Fernando
With all of this thrilling information in thoughts, is ASXC a penny inventory to observe or not?
4. Zomedica Corp. (NYSE: ZOM)
Shares of Zomedica continued rebounding on April twenty second. This marked the second day in a row that the medical system inventory headed again towards the $1 mark. The corporate’s principal focus is on industrial gross sales of its lately launched diagnostic system, TRUFORMA.
The platform provides whole management over the testing course of for animals. It provides extremely delicate and particular immunoassays that permit veterinarians to make scientific selections “sooner and start treating sufferers sooner.”
Final quarter was the large replace that merchants have waited for since 2020: the industrial launch of TRUFORMA. Now Zomedica is seeking to broaden its salesforce and go direct to clients.
Earlier within the month, the corporate introduced that it expanded its gross sales group. Brük Herbst, Chief Business Officer of Zomedica, defined that “A direct gross sales power will considerably enhance our capacity to serve our clients and to promote our merchandise within the veterinary market in the long run.”
In case you’re unfamiliar with the backstory of Zomedica over the previous couple of months, it has included all the pieces from Reddit merchants to Carol Baskin of the present Tiger King. Hypothesis on the launch of business gross sales has helped drive ZOM inventory from underneath $0.10 to over $2.90. However since February, shares have been in a relentless decline as merchants await the outcomes of superior gross sales efforts.
Due to current information on expansionary plans, the market has seen an uptick in momentum. Moreover, during the last 2 classes, ZOM inventory has jumped by as a lot as 32% thus far. Will it nonetheless be one of many penny shares underneath $1 this time subsequent week?